The Cancer Letter

Inside information on cancer research and drug development

Vol.
33
No.
19
May 18, 2007May 18, 2007
Free
DOWNLOAD THE PDF

After ODAC: Questions On ESA Claims, Advertising, Reimbursement Gain Urgency.

Amgen Claimed QOL Benefit Despite FDA Label Change.

“Miracle-Gro for Cancer?” ODAC Members Vent At Amgen And J&J Over Claims, Advertising.

FDA Begins To Examine Its Role In Allowing Misleading Consumer Advertising.

CMS Proposal To Limit ESA Use Is Too Much, Too Fast, Critics Say.

Login

Looking for IP Login?